Omeros (NASDAQ:OMER) Downgraded to Sell at ValuEngine

ValuEngine cut shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a research note released on Thursday morning, ValuEngine reports.

Several other research analysts also recently issued reports on the company. Wedbush restated a hold rating and set a $18.00 price objective on shares of Omeros in a research report on Monday, October 28th. Needham & Company LLC restated a hold rating on shares of Omeros in a research report on Wednesday. BidaskClub downgraded Omeros from a sell rating to a strong sell rating in a research report on Saturday, October 12th. HC Wainwright restated a buy rating and set a $35.00 price objective on shares of Omeros in a research report on Tuesday, November 5th. Finally, Maxim Group set a $32.00 price objective on Omeros and gave the stock a buy rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $25.60.

Shares of NASDAQ:OMER traded down $0.61 during trading on Thursday, hitting $13.20. 525,200 shares of the stock were exchanged, compared to its average volume of 494,576. The company has a fifty day moving average price of $15.37 and a two-hundred day moving average price of $16.90. The company has a market cap of $675.24 million, a PE ratio of -5.95 and a beta of 2.78. Omeros has a 12-month low of $10.30 and a 12-month high of $20.92.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.08. The firm had revenue of $29.86 million for the quarter, compared to analysts’ expectations of $27.19 million. Omeros’s revenue was up 547.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.81) EPS. As a group, research analysts predict that Omeros will post -1.2 EPS for the current year.

In related news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $15.12, for a total transaction of $75,600.00. Following the completion of the transaction, the director now directly owns 35,067 shares in the company, valued at approximately $530,213.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 12.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Cetera Advisors LLC acquired a new position in Omeros in the 3rd quarter valued at $180,000. Bourgeon Capital Management LLC acquired a new position in Omeros in the 3rd quarter valued at $41,000. SG Americas Securities LLC raised its holdings in Omeros by 61.0% in the 3rd quarter. SG Americas Securities LLC now owns 130,823 shares of the biopharmaceutical company’s stock valued at $2,136,000 after acquiring an additional 49,548 shares during the last quarter. California Public Employees Retirement System raised its holdings in Omeros by 62.0% in the 3rd quarter. California Public Employees Retirement System now owns 112,013 shares of the biopharmaceutical company’s stock valued at $1,829,000 after acquiring an additional 42,874 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC raised its holdings in Omeros by 7.0% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 25,680 shares of the biopharmaceutical company’s stock valued at $419,000 after acquiring an additional 1,680 shares during the last quarter. Institutional investors own 53.46% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Recommended Story: Book Value Per Share – BVPS

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.